Background & Aims: Barrett's esophagus (BE) is a highly premalignant disease that predisposes to the development of esophageal adenocarcinoma (EAC); however, the involvement of microRNAs (miRs) in BE-EAC carcinogenic progression is not known. Methods: Esophageal cultured cells (HEEpiC, QhTRT, ChTRT, GihTRT, and OE-33) and esophageal tissues (22 normal epithelia, 24 BE, and 22 EAC) were studied. MiR microarrays and quantitative reverse-transcription polymerase chain reaction (RT-PCR) were employed to explore and verify differentially expressed miRs. Quantitative genomic PCR was performed to study copy number variation at the miR-106b-25 polycistron and MCM7 gene locus on chromosome 7q22.1. In vitro cell proliferation, cell cycle, and apoptosis assays and in vivo tumorigenesis experiments were performed to elucidate biologic effects of the miR-106b-25 polycistron. Western blotting and luciferase assays were performed to confirm direct messenger RNA (mRNA) targeting by the miR-106b-25 polycistron. Results: The miR-106b-25 polycistron exerted potential proliferative, antiapoptotic, cell cycle-promoting effects in vitro and tumorigenic activity in vivo. MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim. This polycistron was upregulated progressively at successive stages of neoplasia, in association with genomic amplification and overexpression of MCM7. In addition, miRs-93 and -106b decreased p21 mRNA, whereas miR-25 did not alter Bim mRNA, suggesting the following discrete miR effector mechanisms: (1) for p21, mRNA degradation; (2) for Bim, translational inhibition. Conclusions: The miR106b-25 polycistron is activated by genomic amplification and is potentially involved in esophageal neoplastic progression and proliferation via suppression of 2 target genes: p21 and Bim.
B
arrett's esophagus (BE) is a highly premalignant disease that predisposes to the development of esophageal adenocarcinoma (EAC), one of the most rapidly increasing cancers in developed nations. 1 The prevalence of BE in US endoscopic series ranges from 0.9% (of 51,311 patients) 2 to 4.5% (of 833 patients). 3 A recent study from Sweden reported a prevalence of BE of 1.6% (among 21,610 patients). 4 These findings imply that more than 3 million individuals may harbor BE in the United States alone. 5 Among these patients, EAC susceptibility is a life-threatening long-term sequela. The incidence of EAC in BE patients is estimated at 1.8 per 1000 person-years, 30-fold higher than in the general population. 6 The molecular genetics of BE and its evolution to EAC have been widely studied. [7] [8] [9] [10] Nonetheless, molecular mechanisms underlying the BE-EAC carcinogenic sequence remain unclear, and a more thorough understanding of the molecular basis of this process would yield several benefits. These benefits include (1) clues to biologic pathways underlying BE-associated neoplastic transformation; (2) useful biomarkers of early cancer detection, disease progression, or ultimate prognosis; and (3) therapeutic targets for intervention in both the prevention and the treatment of this disease.
MicroRNAs (miRs) are a class of abundant, approximately 22 nucleotide noncoding RNAs that mediate posttranscriptional regulation of target messenger RNA (mRNA). Most known functions of miRs relate to negative gene regulation: miRs silence gene expression, usually by interfering with mRNA stability or protein translation. Cancer-specific miR fingerprints have been identified in every tumor type examined. Emerging evidence reveals that a number of miRs are involved in tumorigenesis and/or tumor progression. 11, 12 MiR regulatory mechanisms involved in cancer progression may be viewed as previously missing pieces of a puzzle that is now essential to understanding the complete molecular genetic landscape of cancer progression. However, thus far, there has been only one report describing miR expression in BE and EAC. 13 Herein, we describe novel findings showing that (1) the miR 106b-25 polycistron is activated in BE-associated neoplastic transformation; (2) DNA copy number variation is closely associated with activation of the miR 106b-25 polycistron; and (3) the miR 106b-25 polycistron exerts cell-proliferative and oncogenic effects via key downstream regulatory targets.
Materials and Methods
See also Supplementary Materials and Methods for full description.
Cell Culture
A human esophageal adenocarcinoma cell line, OE-33; 3 metaplastic BE-derived cell lines, QhTRT, ChTRT, and GihTRT 14 ; human normal nonimmortalized primary esophageal epithelial cells, HEEpiC; and human normal lung fibroblasts, WI-38, were used.
Tissue Specimens
All patients provided written informed consent under a protocol approved by the institutional review boards at the University of Maryland and Baltimore Veterans Affairs Medical Centers. Clinicopathologic information is displayed in Supplementary Table 1 .
MiRNA Microarrays
MiRNA Labeling Reagent and Hybridization Kits and Human miR Microarray Kits (Agilent) were used. Data were collected and normalized to nonfunctional small RNA internal controls.
Quantitative Reverse-Transcription Polymerase Chain Reaction for miR Expression
TaqMan MicroRNA Assays, Human (Applied Biosystems, Foster City, CA) were used. All quantitative reverse-transcription polymerase chain reactions (qRTPCRs) were performed in triplicate. RNU6B was used as an internal control.
qRT-PCR for mRNA Expression and Quantitative Genomic DNA PCR
An iQ5 Multicolor Real-Time PCR Detection System and iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) were used for both qRT-PCRs of mRNA expression and quantitative genomic DNA PCRs. Primer sequences are available in Supplementary Table 2. All PCRs were performed in triplicate. Beta-actin was used to normalize mRNA expression levels. An Alu sequence 15 was used to normalize quantitative genomic DNA PCR.
Transfection of miR Mimics and Inhibitors
Synthesized RNA duplexes of miR mimics (MM), miR inhibitors (INH), and small interfering RNA (siRNA) duplex against p21 were purchased from Dharmacon (Lafayette, CO). Cells were transfected with 60 nmol/L of each miR MM, INH, or siRNA.
Cell Proliferation Assay
Cells were plated onto 96-well plates at day 0. At every other day until day 5, Cell Proliferation Reagent WST-1 (Roche, Mannheim, Germany) was added to each well, incubated at 37°C for 1 hour, and an optical density was measured. 
Ki-67 Staining

In Vivo Tumorigenesis
Suspensions of 2 ϫ 10 6 OE-33 cells transfected with miR INHs were mixed with BD Matrigel Basement Membrane Matrix (Becton, Dickinson, and Company, Franklin Lakes, NJ). Cells were injected subcutaneously into both flanks of athymic nude mice (Harlan, Indianapolis, IN) at day 0. Tumor growth was estimated by averaging the volumes of tumors at 8 sites. Tumor volume was calculated according to the following formula: L 2 /2 ϫ W, where L is the length, and W is the width of the tumor. All animal procedures were performed in accordance with institutional guidelines under a protocol approved by the Johns Hopkins Animal Care and Use Committee.
Western Blotting
For CDKN1A (p21 Cip1/WAF1 ), rabbit anti-p21 Cip1/WAF1 from Invitrogen was used, while, for BCL2L11 (Bim), rabbit-anti-Bim from Cell Signaling Technology (Danvers, MA) was used. As an internal control, mouse anti-␤-actin monoclonal antibody was employed.
Luciferase Reporter Assay
Full-length p21 3=-untranslated region (3=UTR) and truncated Bim 3=UTR, common to both Bim EL and Bim L, containing flanking predicted miR-responsive sites, were amplified. We obtained plasmid clones pGL4.13 (Promega, Madison, WI) containing correctly oriented inserts (pGL4.13-P21UTR and pGL4.13-BimUTR). Plasmid clones that contained reversely oriented inserts (pGL4.13-revP21UTR and pGL4.13-revBimUTR) served as universal negative controls. We also constructed plasmids containing p21-3=UTR with mutated seed regions for the predicted miR-93/miR-106b binding sites (pGL4.13-mutP21UTR), along with plasmids containing the Bim-3=UTR with mutated seed regions for the predicted miR-25 binding sites (pGL4.13-mutBimUTR). Primer sequences are available in Supplementary Table 2 . The constructed pGL4.13 vector and an internal control pRL-CMV (Renilla luciferase) vector were cotransfected 24 hours after miR MM or INH transfection. Twenty-four hours after plasmid vector transfection, the luciferase reporter assay was performed using a Dual-Glo luciferase assay kit (Promega). The luminescence intensity of Firefly luciferase was normalized to that of Renilla luciferase.
Statistical Analysis
Results of experiments were displayed as mean Ϯ standard deviation in the Figures. To evaluate statistical significance, Student unpaired t test was used, unless otherwise noted.
Results
MiR Microarrays Define Novel EAC-Specific Candidate Tumor-Suppressive miRs and Oncogenic miRs
As a first approach to studying the involvement of miRs in BE-associated neoplasms, we performed miR microarray investigations of nonimmortalized primary normal esophageal (NE) epithelial cells (HEEpiC), BEderived cell lines (QhTRT, ChTRT, and GihTRT), and an EAC-derived cell line (OE-33). Representative results of these experiments are displayed in Table 1 . Several miRs were aberrantly regulated in BE or EAC cells vs NE cells. In particular, we found that miRs-25, -93, and -106b, all of which form a polycistron on chromosome 7q22.1 (the miR-106b-25 polycistron), were significantly up-regulated in OE-33 cells relative to BE and HEEpiC cells, suggesting possible involvement of this polycistron as an oncogene in BE-associated neoplastic transformation.
qRT-PCR Verifies miR Microarray Results
Next, we validated miR microarray results for 7 miRs that were differentially up-or down-regulated in BE or EAC cells (miRs-25, -93, and -106b in Figure 1A -C; miRs -19b, -100, -125b, and -205 in Supplementary Figure 1 and identified by symbols in footnotes in Table 1 ). Using real-time qRT-PCR, we analyzed the same EAC, BE, and NE cells that had been assessed on miR microarrays. Results of these qRT-PCRs verified those obtained by miR microarray assays, as shown.
Clinical Significance of Aberrant miR Expression
We also performed qRT-PCRs of these differentially expressed miRs (except miR-19b, Figure 1D -F and Supplementary Figure 2 ) in primary human esophageal tissue specimens to address the clinical significance of their aberrant expression. In all cases examined, tissue miR expression results correlated closely with results obtained in cell lines. In particular, all 3 members of the miR-106b-25 polycistron were not significantly up-regulated in BE relative to NE tissues (P ϭ .14, .26, and .35, respectively); however, notably, these miRs were markedly up-regulated in EAC relative to NE and BE. These results implied progressive involvement of the miR-106b-25 polycistron in BE-EAC neoplastic evolution.
Regulatory Mechanisms Underlying miR-25, -93, and -106b Activation
Because the miR-106b-25 polycistron is located within intron 13 of the minichromosome maintenance protein 7 (MCM7) gene on chromosome 7q22.1, we hypothesized that activation of these miRs should correlate with MCM7 "mother gene" activation. To investigate this hypothesis, we first examined MCM7 mRNA levels in the same cell lines using expression microarrays and qRTPCRs ( Figure 2A ). Indeed, we found that MCM7 mRNA expression was up-regulated in BE-derived vs HEEpiC NE cells and, notably, that MCM7 was more markedly upregulated in OE-33 EAC cells than in BE-derived cells, reflecting the same stage-related activation pattern seen with the miR-106b-25 polycistron. Analogous MCM7 mRNA expression results were obtained in tissue specimens ( Figure 2B ). Second, we performed quantitative genomic DNA PCR of the MCM7 mother gene to evaluate whether DNA copy number variation (CNV) constituted a mechanism underlying its activation. Interestingly, this experiment revealed a progressive increase in DNA copy number at the MCM7 locus during neoplastic evolution, proceeding from NE-derived to BE-derived and, finally, to EAC-derived cells ( Figure 2C ). Similarly, we observed significant DNA copy number increases at the MCM7 locus in primary esophageal tissue specimens (NE vs BE, P ϭ .0022; NE vs EAC, P ϭ .00013, Figure 2D ). We also discovered significant de novo CNV of the MCM7 locus in paired NE and EAC tissue specimens from 11 patients (P ϭ .0037 by paired t test in Figure 2E ). Figure 3 showed a close relationship between miRs-25, -93, and -106b expression levels and CNV at the MCM7 locus in tissue specimens (Pearson correlation coefficient test; P ϭ .0014, .011, and .019, respectively).
Biologic Impact of miRs-25, -93, and -106b
In vitro effects. To elucidate cancer-relevant biologic effects of miRs-25, -93, and -106b, we first performed cell number assays using WST-1 reagent. Inhibition of miRs-25, -93, and -106b induced significantly decreased numbers of OE-33 EAC cells ( Figure 4A ). We also performed miR-25-, -93-, and -106b-MM transfection of a BE-derived cell line (ChTRT), as well as of WI-38 normal lung fibroblasts. WI-38 cells were used as representative nonneoplastic cells because HEEpiC cells were not adequate for these experiments due to their resistance to nucleic acid transfection and slow growth (data not shown). We also chose WI-38 cells because their expression levels of miRs-25, -93, and -106b were as low as those In vivo tumorigenesis. Our discovery that the miR106b-25 polycistron induced increased cell numbers in vitro prompted us to evaluate its effects in vivo. As shown in Figure 4D , INHs of miRs-25, -93, and -106b reduced in vivo tumorigenesis in nude mice. For all 3 miR INHs, the most marked inhibitory effects were observed at 5 days posttransfection (day 4 in Figure 4D ). 
The miR-106b-25 Polycistron Directly Regulates p21 and Bim
We next focused our attention on mRNA targets of miRs-25, -93, and -106b. To identify these targets, we employed 2 principal strategies: (1) focusing candidate mRNA searches on results of our phenotypic experiments, eg, cell cycle-and apoptosis-related genes; (2) performing database searches in miR target prediction engines, such as miRBase (http://microrna.sanger.ac.uk/cgi-bin/targets/v4/search. pl), TargetScan (http://www.targetscan.org/vert_40/), and PicTar (http://pictar.bio.nyu.edu/). In our cell-cycle experiments, miRs-93 and -106b exerted internally consistent effects on the G1/S checkpoint: INHs of miRs-93 and -106b both increased the proportion of cells in G1 phase (ie, induced G1 arrest) in OE-33 EAC cells. This finding prompted us to search for G1/S-regulatory proteins, and, in combination with 3=UTR homology searches, we ultimately identified a cyclin-dependent kinase inhibitor and known tumor suppressor gene, CDKN1A (p21 Cip1/WAF1 ). 16 Western blotting revealed that p21 protein expression was sharply reduced by miR-93 and miR-106b MMs and, correspondingly, that p21 protein expression was sharply increased by miR-93 and miR-106b INHs ( Figure 5A and 5B). To evaluate direct binding to and silencing of p21 by miRs-25, -93, and -106b, we then performed luciferase assays of the p21 3=UTR. Luciferase reporter activity was Figure 2A ). (D) Twentyfour NE, 22 BE, and 24 EAC tissues were studied. The average value of NE is set at 1. Horizontal bars indicate average levels. CNV of the MCM7 locus in tissues showed a gradual and significant up-regulation during neoplastic progression from NE to BE to EAC. CNV ratio in EAC averaged 1.37-fold across all specimens, but 29.2% (7/24) of EACs exhibited a significant genomic copy number increase (Ն1.5-fold vs NE). (E) CNV of the MCM7 locus in 11 paired tissue specimens. The MCM7 locus was statistically significantly amplified in EAC tissues relative to paired NE tissues. Paired average fold change (EAC/NE) equaled 1.67 (P ϭ .0037, paired t test).
significantly reduced by miRs-93 and -106b (P ϭ .0015 and .0049 for miR-93 and P ϭ .00078 and .00087 for miR-106b in Figure 5C and 5D, respectively) but not by miR-25 (Supplementary Figure 6A and 6B) , suggesting that miRs-93 and -106b bind directly to the p21 3=UTR and inhibit p21 protein expression.
Similarly, in our apoptosis experiments, miR INHs increased the population of apoptotic cells; thus, in combination with 3=UTR homology searches, we identified the proapoptotic tumor suppressor gene BCL2L11 (BCL2-like 11 or Bim). 17 Bim protein exists in 2 major isoforms, Bim EL and Bim L, both of which have the same 3=UTR sequence. Western blotting revealed that the expression of both Bim isoforms was reduced by a miR-25 MM and increased by a miR-25 INH (Figure 6A and 6B) . Luciferase reporter activity was significantly reduced by miR-25 (P ϭ .0012 and .0096 in Figure 6C and 6D, respectively) but not by miRs-93 and -106b (Supplementary Figure 6C  and 6D ).
Regulatory Effects of the miR-106b-25 Polycistron on p21 and Bim
Next, to investigate whether suppression of p21 and Bim protein expression was due to mRNA degradation, we performed qRT-PCRs of p21 and Bim mRNA after transfecting MMs of miRs-25, -93, and -106b. An siRNA directed against p21 served as a positive control. qRT-PCRs showed that p21 mRNA expression was diminished approximately 30% by the miR-93 MM and 40% by the miR-106b MM vs 94% by the control p21-siRNA (Figure 7A) . Bim mRNA expression did not change following transfection of a miR-25 MM ( Figure 7B ).
Discussion
Although the first miR, lin-4, was discovered in 1993 18 and the second miR, let-7, in 2000 19 in Caenorhabditis elegans, only recently has the study of this class of small regulatory RNAs in humans become more widespread. 20 Experimental evidence that has accumulated in recent years has led oncologists to speculate that unrevealed molecular actors-particularly noncoding RNAs previously classified as "junk"-play important roles in carcinogenesis. In fact, approximately 70% of the genome has been found to be transcribed in mammals. 21 Thus, it is a natural extension of this logic to explore novel noncoding RNA-based mechanisms underlying cancer-related gene dysregulation, even mechanisms unanticipated prior to the discovery of lin-4 and let-7. miRs are now intensively studied in cancer research, and these molecules are predicted to control as much as 30% of all gene expression. 22 To our knowledge, the current findings constitute the first report documenting (1) activation of the miR-106b-25 polycistron by DNA CNV; (2) miR biologic effects in esophageal cells; and (3) in vivo tumorigenic properties of the miR-106b-25 polycistron. Several of the miRs listed in Table 1 have been previously implicated in carcinogenesis. Among miRs up-regulated in the current study, miR200a in ovarian cancer 23 and miR-15b in gastric cancer 24 have been reported as potential onco-miRs. Among miRs that were down-regulated in the current study, members of the let-7 family have been implicated in lung cancer, 25 -25, (B) miR-93, and (C) miR-106b . The average value of NE was set at 1 for both miR expression and CNV determinations. Eleven NE, 5 BE, and 9 EAC specimens were analyzed.
as have members of the miR-34 family in colorectal cancer 26 and of the miR-125 family in prostate cancer. 27 The miR-17-5p-92 and 106a-92 polycistrons have also been documented to function as onco-miRs and are highly homologous to each other, as well as to the miR-106b-25 polycistron. 12 Surprisingly, members of the miR-17-5p-92 and 106a-92 polycistrons (see miRs-17-5p, -19b, -20a, -20b , -92, and -106a in Table 1) were down-regulated in EACs in the current study, suggesting the possibility that the miR-106b-25 polycistron, with its overexpression and high homology to these other polycistrons, may actually compensate for a "perceived" deficit in oncogenic activity of the (down-regulated) miR-17-5p-92 and 106a-92 polycistrons.
Among BE tissue specimens in the current study, there were 12 BE metaplasias, 4 low-grade dysplasias, and 8 high-grade dysplasias (Supplementary Table 1 ). Expression levels of miRs-25, -93, and -106b did not differ significantly between NE and any histologic grade of BE. Moreover, all clinical characteristics, including prognosis (not shown), did not correlate with expression levels of miRs-25, -93, or -106b.
We found that expression of miRs-25, -93, -106b, and MCM7 mRNA in NE, BE, and EAC correlated closely in both cell lines and tissue specimens (Figures 1 and 2A  and 2B) ; however, relative levels of these 3 miRs differed from those of MCM7 mRNA, particularly in EAC cells and tissues. Specifically, in EAC, the fold-change of MCM7 mRNA expression was higher than that of the miR-106b-25 polycistron ( Figures 1A-1C vs 2A and Figures 1D-1F vs 2B ). This contrasting result suggests that unique regulatory mechanisms may also underlie miR106b-25 polycistron vs MCM7 mRNA expression in EAC.
One novel finding was that CNV of the MCM7 locus correlated closely with miR-106b-25 polycistron expression, not only in NE, BE, and EAC cell lines ( Figures  1A-1C vs 2C ), but also in tissues ( Figures 1D-1F vs 2D  and 3) . CNV of MCM7 in the 3 metaplastic BE-derived cell lines (QhTRT, ChTRT, and GihTRT) averaged 1.4-fold higher than in HEEpiC NE cells, whereas CNV of MCM7 in OE-33 EAC-derived cells was much higher (5.8-fold; Figure 2D ). These findings suggest that cumulative CNV occurs during BE neoplastic transformation, possibly at the transition between high-grade dysplasia and EAC. We also observed a close correlation between miR106b-25 polycistron expression and CNV in matched RNA-DNA pairs from the same individuals (P ϭ .0014, .011, and .019, respectively; Figure 3 ). These findings also support the conclusion that the miR-106b-25 polycistron is activated by genomic CNV in at least a proportion of cases. To our knowledge, this is the first direct evidence of a relationship between miR-106b-25 polycistron activation and CNV during neoplastic evolution of any human cancer. There have been several articles describing concomitant de novo genomic amplification, a type of CNV, and miR overexpression. 28, 29 Recent reports have noted that, although most CNV is inherited as a polymorphic trait, 30 de novo CNV can also occur. 31 Figure 2E shows that, among our paired normal-tumor DNA samples, most manifested de novo CNV, ie, somatic DNA amplification, at the MCM7 locus. Although there were only 2 paired BE-EAC samples in the current study, we observed the same trend of de novo CNV for MCM7 in these 2 paired BEs and EACs (relative amplification: 1.293 to 1.504 and 1.159 to 1.177, respectively). Further studies are needed to ascertain whether inherited polymorphic CNV occurs in normal subjects because only normal tissues from EAC patients were included in the current study. Taken together, these results strongly imply that genomic DNA copy number variation at the MCM7 locus was at least partially responsible for coordinate activation of both the miR-106b-25 polycistron and of the MCM7 gene and that this CNV increased progressively during BE-associated neoplastic evolution.
We also studied cancer-related biologic effects of the miR-106b-25 polycistron. All 3 members of this polycistron induced increased cell numbers in normal esophageal, BE-derived, and EAC-derived cell lines. These 3 miRs exhibited unique degrees of cell type-specific targeting in their cell number-increasing effects (Figure 4) , ie, miRs-93 and -106b induced greater increases in cell numbers in normal fibroblasts than did miR-25, whereas miR-25 induced greater increases in cell numbers in BE-derived cells, and miR-93 was the most but miR-25 the least influential in EAC-derived cells. Thus, which member of the miR-106b-25 polycistron most markedly affected cell numbers depended on cell type. The miR-25 MM effect rapidly decreased from days 3 to 5 only in WI-38 but not in ChTRT, QhTRT, and GihTRT cells (QhTRT and GihTRT not shown in Figure 4 ). In contrast, the effects of miRs -93 and -106b persisted at least until day 5 in all cell lines examined. We were unable to determine exactly what caused this unique difference in effects; however, we speculate that WI-38 may have degraded or inactivated miR-25 more rapidly than did the other cell lines we examined. One notable feature of onco-miR polycistrons, including miR-106b-25, is that coordinated activation involving the entire polycistron may enhance its overall oncogenic effect. Moreover, MCM7 itself is oncogenic in prostate cancer. 32 Thus, DNA copy number variation occurring at the MCM7 locus may enhance miR-derived oncogenesis by activating MCM7 simultaneously with the miR-106b-25 polycistron.
OE-33 EAC cells grow slowly in athymic nude mice and are mildly rejected during the course of several weeks (Supplementary Figure 3) with peak tumor size usually occurring within 7 days and maximal tumor volume reaching only 40 mm 3 on average, a size at which experimental effects are difficult to discern. We overcame this difficulty by introducing Matrigel reagent, which accelerated cell growth and appeared to protect these cells from their potentially hostile in vivo environment. According to qRT-PCR measurement of miRs-25, -93, and -106b following miR MM transfections, levels of these miRs remained quite high (24.0-, 23.6-, and 40.0-fold change, respectively) at 6 days post-transfection (see Supplementary Figure 4 ), indicating that these transfected small RNAs continued to be biologically effective for at least 6 days post-transfection. As shown in Figure 4D , antagonists of miRs-25, -93, and -106b exerted inhibitory effects on in vivo tumorigenesis in nude mice, further supporting the in vitro cell number-increasing effects of these miRs.
Negative regulation of miR target mRNAs may be due to either protein translation inhibition or to mRNA degradation. Figure 7A shows that miRs-93 and -106b caused at least some degree of p21 mRNA instability (although not as much as that caused by p21 siRNA), whereas miR-25 did not affect Bim mRNA levels ( Figure 7B ). These findings were further corroborated by Ivanovska et al, 33 who found that miR-106b reduced p21 mRNA by approximately 40% in human mammary epithelial cells. However, our data only partially agree with a recent study of gastric cancers, which showed no apparent effects of miRs-25, -93, and -106b on RNA stability. 34 Taken together, our findings suggest that these 2 mRNA targets are regulated by discrete miR effector mechanisms: (1) for p21, mRNA degradation; (2) for Bim, translational inhibition.
Identifying miR target mRNAs poses a challenge to investigators. Target prediction engines often yield hun- dreds of potential candidate mRNAs, compelling investigators to struggle with the choice of which targets to focus on. One promising strategy to overcome this challenge is to compare global miR and mRNA expression profiles in the same starting materials. 35 Judging from our own results ( Figure 7A and 7B) , p21 would have been detected by such a comparison, whereas Bim would not. Such global comparisons are useful only when miRs effect a decrease in their target mRNA expression levels; moreover, this strategy may also unearth mRNAs whose stability or expression are not directly targeted by particular miRs. Thus, more efficient and innovative approaches to identify mRNA targets of miRs are still needed.
In conclusion, the miR-106b-25 polycistron exerted potential proliferative, antiapoptotic, cell cycle-promoting effects in vitro; tumorigenic properties in vivo; and was progressively activated at successive stages of neoplasia from NE to BE and finally to EAC, potentially because of de novo genomic DNA CNV of the MCM7 locus at chromosome 7q22.1. The miR-106b-25 polycistron thus represents a potential oncogene in BE-EAC carcinogenic evolution, as well as in other human cancers, and may act via regulation of 2 specific target genes: p21 and Bim.
